Lakewood-Amedex Biotherapeutics, Inc.
LABT
$2.32
$0.146.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.29M | 703.40K | 525.20K | 1.13M | 489.30K |
| Depreciation & Amortization | 1.20K | 1.20K | 1.20K | 1.20K | 1.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.79M | 886.80K | 712.10K | 1.88M | 637.40K |
| Operating Income | -3.79M | -886.80K | -712.10K | -1.88M | -637.40K |
| Income Before Tax | -3.77M | -923.30K | -744.90K | -1.91M | -655.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.77M | -923.30K | -744.90K | -1.91M | -655.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.77M | -923.30K | -744.90K | -1.91M | -655.90K |
| EBIT | -3.79M | -886.80K | -712.10K | -1.88M | -637.40K |
| EBITDA | -3.79M | -885.60K | -710.90K | -1.88M | -636.20K |
| EPS Basic | -2.75 | -2.02 | -3.92 | -2.74 | -1.66 |
| Normalized Basic EPS | -1.66 | -0.82 | -0.67 | -1.71 | -0.59 |
| EPS Diluted | -2.75 | -2.02 | -3.92 | -2.74 | -1.66 |
| Normalized Diluted EPS | -1.66 | -0.82 | -0.67 | -1.71 | -0.59 |
| Average Basic Shares Outstanding | 1.42M | 699.50K | 699.60K | 696.80K | 694.50K |
| Average Diluted Shares Outstanding | 1.42M | 699.50K | 699.60K | 696.80K | 694.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |